RELENT research aims at discovering and defining disease mechanisms that allow to stratify patients into those that will respond to a certain treatment and those that may not. We expect that it will become possible to predict for instance, whether specific patients with CD would benefit from a treatment, like TNF inhibitors, and whether the same applies to RA or, conversely, whether the rationale to treat RA patients with drugs inhibiting T-cell signaling, is also valid fo CD.
These measures will not only minimize treatment-associated toxicities, disease-related damage and long-term morbidity but will also reduce health care costs and the devastating societal impact of autoimmune disease. RELENT has implemented measures to evaluate the impact of its research on cost efficacy of change of treatment.